One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company could benefit from the government coverage of its weight loss medicines.

"Dog Jack" is the story of a slave boy and his dog who escape the master's plantation, join the union army, and have to face their former master on the battlefield. The story is inspired by the ...

Singer-songwriter Will Kennedy moves through grief in delicate and unsparing ways using the simple sounds of lo-fi indie rock. When the lily of the valley starts to bloom, it’s one of the surest ...

picture alliance / Contributor / Getty Images Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' weight-loss drugs in ...

Eli Lilly shares were up more than 4% at last check. Get Monthly Picks of Market's Fastest Movers Eli Lilly And Co LLY shares are trading higher Tuesday after the Biden-Harris Administration ...

Biden proposes expanding coverage for anti-obesity drugs Novo shares jump as much as 4.9%, Lilly stock also gains Amgen weight-loss drug trial results miss market expectations Nov 26 (Reuters ...

A spokesperson for Sanofi confirmed plans to implement a similar model as those proposed by Johnson & Johnson and Eli Lilly — to give hospitals rebates for eligible drugs in program, called 340B ...

Lilly’s 20% increase came after it had recorded five straight quarters of at least 28% YOY revenue gains. The company pointed out that its Q3 figure was skewed by its $1.4 billion sale of its ...

Pharmaceuticals stock Eli Lilly and Company (NYSE:LLY) is down by 23% since I last wrote about it in September. At the time, it appeared that the company could come out on top despite challenges ...

Eli Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the activin type IIA receptor to induce weight loss and boost muscle mass.

Chinese biotech Laekna Therapeutics on Wednesday announced a clinical collaboration with Eli Lilly (NYSE:LLY) to develop an obesity therapy that can avoid loss of muscle mass, a problem often ...